121 patents currently held
45 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
14 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Of the 45 now held by other companies, 13 name Haleon US Holdings LLC as their current owner, and 32 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
91
Ending by 2030
Nov 2026
Next term end
61
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2032 · Medium confidence
Also notable
Ends Jul 2031 · High confidence
Also notable
Ends Apr 2027 · High confidence
Compositions Relating to a Mutant Clostridium Difficile Toxin and Methods Thereof
US 11,535,652
Cited by 6 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2032.
Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine
US 8,669,273
Cited by 23 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Pneumococcal Dosing Regimen
US 10,406,220
Cited by 23 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2027.
Formerly held, still cited
Notable
Ends no later than Aug 2029 · Medium confidence
The most cited patent in this portfolio, cited by 146 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2029. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Aptevo Research and Development LLC
Also notable
Ends Jul 2031 · High confidence
Cited by 57 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Oral Formulations and Lipophilic Salts of Methylnaltrexone (US 10,307,417) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 4 fees due Feb 4 to 25, 2027 · next Feb 4
- 3 fees due Mar 8 to 22, 2027 · next Mar 8
- 2 fees due May 3 to 10, 2027 · next May 3
- 4 fees due Jun 15 to 24, 2027 · next Jun 15
- 1 fee due Jul 5, 2027The maintenance fee for Processes for Making Hydrazides (US 9,227,924) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine (US 9,265,784) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Compositions Relating to a Mutant Clostridium Difficile Toxin and Methods Thereof (US 10,597,428) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Oral Formulations and Lipophilic Salts of Methylnaltrexone (US 9,314,461) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
- 6 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 61 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Maleate Salts of (E)-N-{4-[3-Chloro-4-(2-Pyridinylmethoxy)ANILINO]-3-Cyano-7-Ethoxy-6-Quinolinyl}-4-(DIMETHYLAMINO)-2-Butenamide and Crystalline Forms Thereof | 11 in force | to Jul 2031 |
| Triazine Compounds as PI3 Kinase and Mtor Inhibitors | 8 in force | to Dec 2029 |
| Designer Osteogenic Proteins | 6 in force | to Aug 2031 |
| Oral Formulations and Lipophilic Salts of Methylnaltrexone | 6 in force | to Mar 2031 |
| Compositions Relating to a Mutant Clostridium Difficile Toxin and Methods Thereof | 5 in force | to Jul 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,767,678 | Crystalline Forms of 4-[(2,4-Dichloro-5-Methoxyphenyl)AMINO]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)PROPOXY]-3-Quinolinecarbonitrile and Methods of Preparing the Same In force · High confidence | In force | High confidence | |
| US 10,729,672 | Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 In force · Medium confidence | In force | Medium confidence | |
| US 7,811,567 | Methods of Using Antibodies Against Human IL-22 In force · High confidence | In force | High confidence | |
| US 7,846,444 | Methods of Using Antibodies Against Human IL-22 In force · High confidence | In force | High confidence | |
| US 8,273,862 | Processes for the Convergent Synthesis of Calicheamicin Derivatives In force · Medium confidence | In force | Medium confidence | |
| US 8,546,549 | Processes for the Convergent Synthesis of Calicheamicin Derivatives In force · Low confidence | In force | Low confidence | |
| US 9,802,890 | Processes for the Convergent Synthesis of Calicheamicin Derivatives In force · Medium confidence | In force | Medium confidence | |
| US 10,343,989 | Processes for the Convergent Synthesis of Calicheamicin Derivatives In force · Medium confidence | In force | Medium confidence | |
| US 7,625,560 | Humanized Antibodies That Recognize Beta Amyloid Peptide In force · High confidence | In force | High confidence | |
| US 7,683,051 | Crystalline Polymorph of Bazedoxifene Acetate In force · High confidence | In force | High confidence |
Also on record, not counted in the 121: 45 patents in force now held by others · 471 patents ended · 1 application pending · 418 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.